Ib Summarizerv0.1.0

A clinical research coordinator needs to review the Investigator's Brochure (IB) for a new oncology drug before site initiation. They use the IB Summarizer to extract core safety information, including ADRs and contraindications, to prepare training materials for investigators.

A regulatory affairs specialist compiles safety data for an FDA IND submission. The tool extracts and formats safety updates from the IB, ensuring all recent changes are captured in structured JSON for integration into submission documents.

Members of a Data Safety Monitoring Board need a concise summary of safety information for a drug in a Phase II trial. The summarizer generates a markdown report highlighting known ADRs, special population precautions, and overdose management, enabling quick decision-making.

A clinical development team from a biotech startup collaborates with CROs. They use the tool to create a standardized safety summary from the IB, which is shared across teams to ensure consistent understanding of drug risks.

A medical writer updates an IB with new safety information from recent studies. They use the summarizer to extract and compare the new findings with existing safety data, ensuring the IB remains current.

The IB Summarizer is offered as a module within a larger clinical trial management platform. Pharmaceutical companies subscribe to access automated IB summarization features, paying a monthly fee per user.

A clinical research consulting firm uses the tool internally to deliver faster IB reviews to clients. The service is billed per project or as part of a broader consulting engagement.

The summarizer is exposed via API for integration into existing clinical systems. Users are charged per document processed, making it accessible for occasional use by smaller biotechs.